StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Inhibikase Therapeutics's enterprise value was $56.19M on Nov 11, 2026, against $36.39M a year earlier. Over the last 5 years it ranged from -$17.88M to $145.98M, with a median of $260.41K.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$56.19M-26.1%
2025Dec 31, 2025$76.03M+259.3%
2024Dec 31, 2024$21.16M–
2023Dec 29, 2023-$9.87M–
2022Dec 30, 2022-$13.78M–
2021Dec 31, 2021-$9.64M–

More Inhibikase Therapeutics figures

See a number that looks wrong?